Hundreds of new jobs are to be created in Kilkenny by medtech giant Abbott, including 800 permanent roles and 300 construction roles.
Construction has commenced on Abbott’s seventh manufacturing facility in Ireland which will produce its FreeStyle Libre 3 glucose monitoring system
More than 800 permanent roles are to be created at the facility as well as 300 roles during the construction phase.
“This new facility, together with our diabetes care facility in Donegal, will help us meet the growing demand and bring new highly skilled jobs to the community”
It is understood that recruitment has already commenced and 50 roles have been filled.
Manufacturing will commence in Kilkenny in 2024.
Abbott has more than 70 years of history in Ireland
Abbott was one of the first multinational companies to establish in Ireland and is the only one with operations in all four provinces. This new investment will bring Abbott’s total employment in the country to approximately 6,000 people across 10 sites, including seven manufacturing operations.
The new plant will produce the FreeStyle Libre 3 glucose monitoring system, which features the world’s smallest and thinnest glucose sensor for people with diabetes.
The new roles will be in engineering, quality control, medical device manufacturing and other science-based areas. The company is actively recruiting and anyone wishing to learn more about the opportunities available or register their interest in working with Abbott, can visit https://www.abbott.com/careers.html.
“With a footprint in all four provinces, Abbott has played a leading role over the past 77 years in establishing Ireland as a location for the global medtech sector,” said Minister for Justice and Minister of Further and Higher Education, Research, Innovation and Science Simon Harris, TD.
“This new investment in Kilkenny will add to the high value STEM jobs already created in the South-East region by Abbott at its vascular manufacturing facility in Clonmel. This is an important investment for Ireland, and I am delighted to congratulate Abbott on this new diabetes care manufacturing facility in Kilkenny.”
Abbott announced in August last year that it is investing €440 million in significantly expanding manufacturing operations for its Diabetes Care business in Ireland. In addition to the new manufacturing facility in Kilkenny, the company announced the expansion of operations at its existing facility in Donegal.
“Abbott’s FreeStyle Libre is the number one sensor-based glucose monitoring system in the world, having changed the lives of 4.5 million people across more than 60 countries by providing breakthrough technology that is accessible and affordable,” said Jared Watkin, senior vice president of Abbott’s Diabetes Care business.
“This new facility, together with our diabetes care facility in Donegal, will help us meet the growing demand and bring new highly skilled jobs to the community.”
The building of Abbott’s new facility in Kilkenny is supported by the Irish Government through IDA Ireland.
Mary Buckley, Interim CEO said: “This investment, announced last year, is a further testament to the deep roots the company has in Ireland. IDA Ireland’s strategy to win investments and jobs in regional locations includes encouraging and supporting established companies to develop additional regional sites and this is a prime example. This new manufacturing facility will deliver a substantial boost to the economy of the South East.”